Tumor samples grown in dishes to predict immunotherapy response
Part of Cancer, Lungs & breathing clinical trials.
This study takes small biopsy samples of your lung cancer and grows them in a dish to predict how well immunotherapy will work. If you qualify, you’ll receive standard immunotherapy (anti-PD-1/L1, with or without anti-CTLA-4), and the results from the dish-grown tumors will be compared to your real-world response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or a legally authorized representative) can understand the study and sign informed consent.
- You have advanced or metastatic non-small cell lung cancer (NSCLC) and are 18 or older.
- You have not started immunotherapy yet (it’s immunotherapy-naive).
- Your health and daily functioning are good enough (ECOG score 0 to 2).
- Your scans show measurable cancer, with at least one spot that can be followed, and you have a lesion that can be safely biopsied for enough tissue to grow tumor “mini-organs” (tumoroids).
- You will receive anti–PD-1/PD-L1 immunotherapy (with or without anti–CTLA-4) as part of standard care; you must follow required pregnancy prevention rules during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
This study looks at how your body reacts to checkpoint inhibitors (immunotherapy drugs like Keytruda or Opdivo) for NSCLC. It involves blood tests to check for antibodies your immune system might make against the drug.
This study looks at the genetic makeup of lung cancer tumors after patients receive immunotherapy before surgery. It aims to understand why some tumors do not completely disappear and may help guide future treatments.
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
This trial tests whether a “liquid biopsy” blood test can help predict how well first immunotherapy will work for people with stage IV lung cancer. It may help doctors choose the most effective treatment strategy sooner.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.